Elucidation of the pharmacokinetics of methotrexate and establishment of the optimum medication method in Japanese rheumatoid arthritis patients.
Not Applicable
Recruiting
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000008514
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who cannot be treated with MTX 2)Patients who cannot be treated with biologic agents 3)Patients who are pregnant, who are nursing or who hope to be pregnant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ow disease activity(SDAI<11 ) rate at week 12
- Secondary Outcome Measures
Name Time Method 1. Concentration of MTX-PG at week 4, 8, 12, 24 and 36 2. Remission rate (SDAI<3.3) at week 12,24 and 36 3. Radiological remission rate 4. Adverse effect rate